Related Experiment Videos
Low-affinity E-rosette-blocking factor in hemodialysis-treated patients in chronic renal failure
Clinical Immunology and Immunopathology
|March 1, 1983
Summary
Dialysis patients show reduced total E-rosette-forming cells (t-ERFC), categorized by duration of hemodialysis. A rosette-blocking factor (RBF) was present in all groups, suggesting dialysis may remove an anti-RBF substance.
Area of Science:
- Immunology
- Nephrology
Background:
- Renal failure impacts immune cell function.
- Hemodialysis is a critical treatment for end-stage renal disease.
Purpose of the Study:
- To classify renal failure patients on hemodialysis based on total E-rosette-forming cells (t-ERFC).
- To investigate the role of a rosette-blocking factor (RBF) in these patients.
Main Methods:
- Enumeration of total E-rosette-forming cells (t-ERFC) in 30 hemodialysis patients.
- Classification into three groups based on t-ERFC levels.
- Demonstration and partial absorption of rosette-blocking factor (RBF).
Main Results:
- Patients were grouped by t-ERFC: normal (Group 1), reversibly reduced (Group 2A), and irreversibly reduced (Group 2B).
- Duration of dialysis treatment correlated with t-ERFC levels (Group 1 < Group 2A < Group 2B).
- A rosette-blocking factor (RBF) was found in all groups, affecting low-affinity ERFC.
Conclusions:
- Hemodialysis duration is a key factor in classifying t-ERFC levels in renal failure patients.
- A rosette-blocking factor (RBF) is present in hemodialysis patients.
- Dialysis may remove an anti-RBF substance, as evidenced by increased RBF activity post-dialysis.